PureTech Health plc cash flow to debt ratio of -435.65% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

PureTech Health plc's free cash flow has increased -36.50% from $-134.38M last year to $-85.34M, signaling increasing performance

PureTech Health plc's debt to equity ratio is 0.06, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

PureTech Health plc's debt has increased relative to shareholder equity from 0.05 last year to 0.06 today, signaling weakened financials

PureTech Health plc has negative EBITDA, making leverage ratio unreliable

PureTech Health plc's interest coverage ratio is -2.16, which means that the company struggles to meet interest obligations, signaling financial risk.

PureTech Health plc's profit margin has decreased (-312.53%) in the last year from 1.11K% to -2.36K%, signaling decreasing performance

PureTech Health plc's short-term assets of $305.02M exceed its short-term liabilities of $46.31M

PureTech Health plc's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

PureTech Health plc's return on equity of -31.83%, is lower than 15.00%, indicating bad performance

PureTech Health plc's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

PureTech Health plc had positive net income in only 1.00 out of 5 years, indicating unstable earnings

PureTech Health plc has negative free cash flow, indicating the company is burning cash rather than generating it

PureTech Health plc has negative free cash flow, indicating cash burn

PureTech Health plc's yearly earnings has decreased -305.08% since last year from $53.51M to $-109.74M, signaling decreasing performance

PureTech Health plc's yearly revenue has decreased -3.50% since last year from $4.83M to $4.66M, signaling decreasing performance

ROIC -19.64% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

PureTech Health plc's 3-year revenue CAGR of 30.63% is positive, indicating growing revenue over the past 3 years

PureTech Health plc had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance

PureTech Health plc had positive ROE in only 1.00 out of 5 years, indicating inconsistent returns on equity

PureTech Health plc has insufficient data to evaluate this check.

PureTech Health plc has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

PureTech Health plc is undervalued relative to its fair value price of 21.37 based on EBITDA multiple model

PureTech Health plc has negative or missing EBITDA, making EV/EBITDA ratio unreliable

PureTech Health plc is overvalued relative to its fair value price of -366.25 based on Earnings Fair Value model

PureTech Health plc has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

PureTech Health plc has a price-to-book ratio of 0.14x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

PureTech Health plc has a price-to-sales ratio of 9.02x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue